Home / Health / Cancer Breakthrough: Drug Targets 'Undruggable' Protein
Cancer Breakthrough: Drug Targets 'Undruggable' Protein
20 Apr
Summary
- New drug daraxonrasib shows significant survival benefit in pancreatic cancer patients.
- The drug demonstrated a 60% reduced risk of death compared to chemotherapy.
- Revolution Medicines' drug targets RAS proteins previously considered 'undruggable'.
A revolutionary drug, daraxonrasib, developed by Revolution Medicines, is showing significant promise in extending the lives of pancreatic cancer patients. Recent trial results indicate that patients treated with daraxonrasib lived a median of 13.2 months, nearly double the 6.7 months seen with traditional chemotherapy. This experimental therapy reduced the risk of death by 60% compared to chemotherapy.
This development is particularly significant for pancreatic cancer, a disease with a grim prognosis and limited treatment options; the five-year survival rate for Stage 4 is only 3%. Daraxonrasib works by inhibiting RAS proteins, which drive tumor growth in about 90% of pancreatic cancers, as well as other cancers. While side effects can occur, patients like former Senator Ben Sasse have reported substantial reductions in tumor markers.
Further advances are also on the horizon. Northwestern University reported this week that another experimental drug, when combined with chemotherapy, slashed the risk of death by 38% in pancreatic cancer patients. Additionally, artificial intelligence is showing potential in detecting the disease earlier on CT scans. These advancements offer a hopeful outlook against a disease historically resistant to treatment.
